**Suppl. Table 1** Comorbidities and DFS70 status in the studied subjects with ILD.

|  |  |  |  |
| --- | --- | --- | --- |
| **Comorbidity** | **N=260 (%)** | **DFS70 status** | **p\*** |
|  |  | **Pos (N=182)** | **Neg (N=78)** |  |
| **Arterial Hypertension** | 103 (40) | 74 | 29  | 0.678 |
| **Coronary Artery Diseases** | 99 (38) | 71  | 28  | 0.667 |
| **Arthrosis** | 68 (26) | 40  | 28  | 0.022 |
| **Diabetes** | 67 (26) | 33 | 34 | 0.998 |
| **Hypercholesterolemia** | 53 (20) | 38 | 15 | 0.776 |
| **GERD (treated)** | 48 (18) | 37 | 11 | 0.387 |
| **Sleep Apnea** | 42 (16) | 30 | 12 | 0.971 |
| **Emphysema** | 37 (14) | 28  | 9 | 0.561 |
| **Pulmonary Hypertension** | 29 (11) | 22  | 7  | 0.526 |
| **Cancer (all types)** | 16 (6) | 13 | 3  | 0.406 |
| **Lung cancer** | 12 (5) | 10 | 2 | 0.519 |
| **Others** | 15 (6) | 6  | 9 | 0.857 |

\* Calculated by Chi squared or Fisher's exact test

**Suppl. Table 2** Logistic regression analysis for verifying the baseline factors associated with CTD development

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Univariate** |  | **Multivariate\*** |
|  | OR | 96%CI | p |  | OR | 96%CI | p |
| Age | 0.966 | 0.909-1.026 | 0.257 |  |  |  |  |
| Gender (Female) | 2.697 | 0.530-13.721 | 0.232 |  |  |  |  |
| Smoking habits (smoker) | 1.827 | 0.441-7.577 | 0.406 |  |  |  |  |
| BAL Lymphocytosis (>13%) | 1.030 | 0.993-1.068 | 0.281 |  |  |  |  |
| HRCT pattern (NSIP) | 11.999 | 2.362-60.946 | 0.003 |  | 13.233 | 2.793-62.699 | 0.001 |
| ANA+/DFS70- status | 3.356 | 0.441-7.577 | 0.049 |  | 3.536 | 1.050-11.911 | 0.042 |

\* Calculated by using backward stepwise conditional method (5 steps), verified by forward conditional method (probability for stepwise entry 0.05, for removal 0.1).

**Suppl. Table 3 .** Clinical parameters of ILD patients according to anti-DFS70 antibody status.

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **anti-DFS70 status of** **NSIP** |  | **anti-DFS70 status of** **IPF** |
|  **(+)**n=12 | **(-)**n=88 |  | **(+)**n=31 |  **(-)**n=129 |
| **Pulmonary function** |  |  |  |  |  |
| **FVC**, %pred. | 65±6 | 70±2 |  | 72±3 | 70±2 |
| **FEV1**, %pred. | 64±6 | 69±2 |  | 75±3 | 71±2 |
| **DLco**, %pred. | 37±3 | 49±4 |  | 48±3\* | 41±1 |
| **TLC**, %pred. | 66±4 | 68±2 |  | 69±2 | 66±1 |
| **Blood gas analysis** | 　 | 　 |  | 　 | 　 |
| **PaO2**, mmHg | 75±3 | 74±1 |  | 75±2 | 71±1 |
| **PaCO2,** mmHg | 35±0.8\* | 38±0.4 |  | 39±0.5 | 38±0.3 |
| **AaDO2**, mmHg | 31±2 | 29±1 |  | 26±2\* | 31±1 |
| **SaO2**, % | 96±0.5 | 95±0.4 |  | 96±0.4 | 95±0.3 |
|

|  |
| --- |
| **BALF cell differential,**  |
| **PaO2**, mmHg |
| **PaCO2,** mmHg |
| **AaDO2**, mmHg |
| **SaO2**, % |

 |  |  |  |  |  |
| **Total cells** ×104 / 100 mL recovery | 7±0.8 | 9.5±2 |  | 7±2 | 6±0.7 |
|

|  |
| --- |
| **Macrophages,** % |
| **PaO2**, mmHg |
| **PaCO2,** mmHg |
| **AaDO2**, mmHg |
| **SaO2**, % |

 | 64±3\* | 59±5 |  | 70±2.5 | 76±4 |
|

|  |
| --- |
| **Neutrophils,** % |
| **PaO2**, mmHg |
| **PaCO2,** mmHg |
| **AaDO2**, mmHg |
| **SaO2**, % |

 | 10±2\* | 14±3 |  | 11±2 | 19±2 |
|

|  |
| --- |
| **Lymphocytes,** % |
| **PaO2**, mmHg |
| **PaCO2,** mmHg |
| **AaDO2**, mmHg |
| **SaO2**, % |

 | 16±2\* | 19±4 |  | 10.5±1 | 9.5±2 |
|

|  |
| --- |
| **Eosinophils,** % |
| **PaO2**, mmHg |
| **PaCO2,** mmHg |
| **AaDO2**, mmHg |
| **SaO2**, % |

 | 4±0.9\* | 5±2 |  | 3±0.6 | 2.5±0.4 |
| **Biomarker** |  |  |  |  |  |
| **LDH**, U/l | 261±12 | 288±9 |  | 252±10\* | 286±6 |

Values are expressed as mean ± SEM.

\* p<0.05 vs. anti-DFS70 (-).